- Home
- Publications
- Publication Search
- Publication Details
Title
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?
Authors
Keywords
-
Journal
Current Atherosclerosis Reports
Volume 24, Issue 12, Pages 995-1004
Publisher
Springer Science and Business Media LLC
Online
2022-11-16
DOI
10.1007/s11883-022-01074-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications
- (2022) Massimiliano Ruscica et al. CARDIOVASCULAR RESEARCH
- Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis
- (2022) Jing Li et al. HEART
- Proprotein convertase PCSK9 affects expression of key surface proteins in human pancreatic beta cells via intra- and extracellular regulatory circuits.
- (2022) Kevin Saitoski et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial
- (2022) Petr Ostadal et al. Lancet Diabetes & Endocrinology
- Lipid traits and type 2 diabetes risk in African ancestry individuals: A Mendelian Randomization study
- (2022) Opeyemi Soremekun et al. EBioMedicine
- Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system
- (2022) Chunmei Ji et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid–Based Therapy Era
- (2022) Ioanna Gouni-Berthold et al. Current Atherosclerosis Reports
- Inclisiran: How Widely and When Should We Use It?
- (2022) Angela Pirillo et al. Current Atherosclerosis Reports
- Pancreatic PCSK9 controls the organization of the β-cell secretory pathway via LDLR-cholesterol axis
- (2022) Algerta Marku et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease
- (2022) Arjen J. Cupido et al. JAMA Cardiology
- Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease
- (2022) Michelle L. O’Donoghue et al. CIRCULATION
- Common and Rare PCSK9 Variants Associated with Low-Density Lipoprotein Cholesterol Levels and the Risk of Diabetes Mellitus: A Mendelian Randomization Study
- (2022) Lung-An Hsu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT
- (2022) Raul D Santos et al. Lancet Diabetes & Endocrinology
- Using Mendelian Randomization to Improve the Design of Randomized Trials
- (2021) Brian A. Ference et al. Cold Spring Harbor Perspectives in Medicine
- Lipid Lowering Drugs: Present Status and Future Developments
- (2021) Massimiliano Ruscica et al. Current Atherosclerosis Reports
- PCSK9: a view beyond the canonical cholesterol lowering impact
- (2021) Chiara Macchi et al. AMERICAN JOURNAL OF PATHOLOGY
- Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function
- (2021) Stéphane Ramin-Mangata et al. ATHEROSCLEROSIS
- Substantial PCSK9 inactivation in β-cells does not modify glucose homeostasis or insulin secretion in mice
- (2021) Marie-Line Peyot et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Cardiovascular Benefit of Lowering LDL Cholesterol Below 40 mg/dl
- (2021) Nicholas A. Marston et al. CIRCULATION
- The Multifaceted Biology of PCSK9
- (2021) Nabil G Seidah et al. ENDOCRINE REVIEWS
- Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study
- (2021) Adam Goldman et al. European Journal of Preventive Cardiology
- Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Ezetimibe on Risk of New-Onset Diabetes: A Systematic Review and Meta-Analysis of Large, Double-Blinded Randomized Controlled Trials
- (2020) Sarah W. Chiu et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
- Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors
- (2020) David Preiss et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis
- (2020) Paul Guedeney et al. European Heart Journal-Cardiovascular Pharmacotherapy
- How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol
- (2020) Angelos D Karagiannis et al. EUROPEAN HEART JOURNAL
- Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association
- (2019) Connie B. Newman et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Cholesterol metabolism, pancreatic β-cell function and diabetes
- (2019) Carla Perego et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study
- (2019) Robert S. Rosenson et al. DIABETOLOGIA
- Association of Lowering Low‐Density Lipoprotein Cholesterol With Contemporary Lipid‐Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta‐Analysis
- (2019) Safi U. Khan et al. Journal of the American Heart Association
- Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials
- (2019) Paul Guedeney et al. EUROPEAN HEART JOURNAL
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
- (2019) Kausik K Ray et al. Lancet Diabetes & Endocrinology
- Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
- (2019) Amand F. Schmidt et al. BMC Cardiovascular Disorders
- Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes
- (2019) Stéphane Ramin-Mangata et al. ATHEROSCLEROSIS
- Comment on de Carvalho et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364–367
- (2018) Ye-Xuan Cao et al. DIABETES CARE
- Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial
- (2018) Kausik K. Ray et al. DIABETES OBESITY & METABOLISM
- PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor
- (2018) Lorenzo Da Dalt et al. EUROPEAN HEART JOURNAL
- Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract
- (2018) François Mach et al. EUROPEAN HEART JOURNAL
- Impact of Lipids on Cardiovascular Health
- (2018) Brian A. Ference et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PCSK9 inhibitor therapy: A systematic review and meta-analysis of metabolic and cardiovascular outcomes in patients with diabetes
- (2018) Matteo Monami et al. DIABETES OBESITY & METABOLISM
- PCSK9 inhibitors: clinical evidence and implementation
- (2018) Marc S. Sabatine Nature Reviews Cardiology
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nature as a Trialist?
- (2017) Sonja A. Swanson et al. EPIDEMIOLOGY
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
- (2017) Brian A. Ference et al. EUROPEAN HEART JOURNAL
- Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration
- (2017) Brian A Ference et al. EUROPEAN HEART JOURNAL
- Bococizumab for the treatment of hypercholesterolaemia
- (2017) Nicola Ferri et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab
- (2017) Jennifer G. Robinson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
- (2017) Robert P Giugliano et al. LANCET
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
- (2017) Marc S Sabatine et al. Lancet Diabetes & Endocrinology
- PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
- (2017) Amand F Schmidt et al. Lancet Diabetes & Endocrinology
- Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions
- (2016) Michael G. Silverman et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association Between Low-Density Lipoprotein Cholesterol–Lowering Genetic Variants and Risk of Type 2 Diabetes
- (2016) Luca A. Lotta et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
- (2016) Brian A. Ference et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of New-Onset Diabetes and Cardiovascular Risk Reduction From High-Dose Statin Therapy in Pre-Diabetics and Non – Pre-Diabetics
- (2015) Payal Kohli et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials
- (2015) Daniel I Swerdlow et al. LANCET
- Statin therapy and related risk of new-onset type 2 diabetes mellitus
- (2014) Massimiliano Ruscica et al. European Journal of Internal Medicine
- PCSK9 is expressed in pancreatic δ-cells and does not alter insulin secretion
- (2009) Cédric Langhi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Low- and High-Density Lipoproteins Modulate Function, Apoptosis, and Proliferation of Primary Human and Murine Pancreatic β-Cells
- (2009) Sabine Rütti et al. ENDOCRINOLOGY
- PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities
- (2009) Majambu Mbikay et al. FEBS LETTERS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started